{"id":35572,"date":"2026-06-26T15:26:47","date_gmt":"2026-06-26T09:56:47","guid":{"rendered":"https:\/\/www.delveinsight.com\/blog\/?p=35572"},"modified":"2026-06-26T15:26:49","modified_gmt":"2026-06-26T09:56:49","slug":"trodelvy-approval-for-mtnbc","status":"publish","type":"post","link":"https:\/\/www.delveinsight.com\/blog\/trodelvy-approval-for-mtnbc","title":{"rendered":"TRODELVY\u2019s First-Line TNBC Approval: Gilead\u2019s Big Bet Reshapes the TROP2 ADC Battlefield"},"content":{"rendered":"<div id=\"ez-toc-container\" class=\"ez-toc-v2_0_76 counter-hierarchy ez-toc-counter ez-toc-white ez-toc-container-direction\">\n<p class=\"ez-toc-title\" style=\"cursor:inherit\">Table of Contents<\/p>\n<label for=\"ez-toc-cssicon-toggle-item-6a3eebcad3ff0\" class=\"ez-toc-cssicon-toggle-label\"><span class=\"\"><span class=\"eztoc-hide\" style=\"display:none;\">Toggle<\/span><span class=\"ez-toc-icon-toggle-span\"><svg style=\"fill: #999;color:#999\" xmlns=\"http:\/\/www.w3.org\/2000\/svg\" class=\"list-377408\" width=\"20px\" height=\"20px\" viewBox=\"0 0 24 24\" fill=\"none\"><path d=\"M6 6H4v2h2V6zm14 0H8v2h12V6zM4 11h2v2H4v-2zm16 0H8v2h12v-2zM4 16h2v2H4v-2zm16 0H8v2h12v-2z\" fill=\"currentColor\"><\/path><\/svg><svg style=\"fill: #999;color:#999\" class=\"arrow-unsorted-368013\" xmlns=\"http:\/\/www.w3.org\/2000\/svg\" width=\"10px\" height=\"10px\" viewBox=\"0 0 24 24\" version=\"1.2\" baseProfile=\"tiny\"><path d=\"M18.2 9.3l-6.2-6.3-6.2 6.3c-.2.2-.3.4-.3.7s.1.5.3.7c.2.2.4.3.7.3h11c.3 0 .5-.1.7-.3.2-.2.3-.5.3-.7s-.1-.5-.3-.7zM5.8 14.7l6.2 6.3 6.2-6.3c.2-.2.3-.5.3-.7s-.1-.5-.3-.7c-.2-.2-.4-.3-.7-.3h-11c-.3 0-.5.1-.7.3-.2.2-.3.5-.3.7s.1.5.3.7z\"\/><\/svg><\/span><\/span><\/label><input type=\"checkbox\"  id=\"ez-toc-cssicon-toggle-item-6a3eebcad3ff0\"  aria-label=\"Toggle\" \/><nav><ul class='ez-toc-list ez-toc-list-level-1 ' ><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-1\" href=\"https:\/\/www.delveinsight.com\/blog\/trodelvy-approval-for-mtnbc\/#The_TRODELVY_Track_Record_Not_a_Clean_Sweep\" >The TRODELVY Track Record: Not a Clean Sweep<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-2\" href=\"https:\/\/www.delveinsight.com\/blog\/trodelvy-approval-for-mtnbc\/#TRODELVY_vs_DATROWAY_The_Defining_Rivalry_in_TROP2_ADCs\" >TRODELVY vs. DATROWAY: The Defining Rivalry in TROP2 ADCs<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-3\" href=\"https:\/\/www.delveinsight.com\/blog\/trodelvy-approval-for-mtnbc\/#Why_TNBC_is_Such_High-Stakes_Real_Estate\" >Why TNBC is Such High-Stakes Real Estate?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-4\" href=\"https:\/\/www.delveinsight.com\/blog\/trodelvy-approval-for-mtnbc\/#Conclusion\" >Conclusion<\/a><\/li><\/ul><\/nav><\/div>\n\n<p><strong><em>Summary<\/em><\/strong><\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li><em>TRODELVY redefines first-line mTNBC treatment as the only approved ADC independent of PD-L1 expression.<\/em><\/li>\n\n\n\n<li><em>TRODELVY sets a new standard as Europe\u2019s first ADC and first novel therapy in two decades for eligible patients with first-line metastatic triple-negative breast cancer.<\/em><\/li>\n\n\n\n<li><em>Approval was based on ASCENT-03 data demonstrating a highly statistically significant and clinically meaningful progression-free survival benefit for TRODELVY over chemotherapy in PD-(L)1 inhibitor-ineligible patients<\/em><\/li>\n\n\n\n<li><em>The battle within the rapidly growing Trop-2 ADC market is intensifying, where Gilead now faces escalating competition from AstraZeneca\/Daiichi Sankyo and Kelun-Biotech.<\/em><\/li>\n<\/ul>\n\n\n\n<p>For nearly two decades, patients with metastatic triple-negative breast cancer (TNBC) who couldn&#8217;t tolerate immunotherapy had no new options. That changed this week. <strong>Gilead Sciences<\/strong> just landed back-to-back regulatory wins for <strong>TRODELVY (sacituzumab govitecan-hziy)<\/strong>, first from the European Commission, then a day later from the US FDA, clearing the Trop-2-directed antibody-drug conjugate (ADC) as a <a href=\"https:\/\/www.delveinsight.com\/report-store\/metastatic-triple-negative-breast-cancer-market\">front-line monotherapy for TNBC patients<\/a> who aren&#8217;t candidates for PD-1\/PD-L1 inhibitors. The FDA didn&#8217;t stop there: it also expanded TRODELVY&#8217;s label for a second TNBC setting in the same week, doubling down on a drug that&#8217;s had a genuinely up-and-down few years.<\/p>\n\n\n\n<p>This is more than a routine label expansion. It&#8217;s the moment TRODELVY graduates from a second-line workhorse into a true front-line contender, and it&#8217;s also the moment the Trop2 ADC wars officially go three-way. Gilead, <strong>AstraZeneca\/Daiichi Sankyo<\/strong>, and a fast-moving Chinese challenger are now scrapping for position in one of oncology&#8217;s most competitive, most lucrative real estate plays.<\/p>\n\n\n\n<p>TRODELVY&#8217;s new front-line indication covers adults with unresectable, locally advanced, or metastatic TNBC who have not received prior systemic therapy for metastatic disease and who are not eligible for <a href=\"https:\/\/www.delveinsight.com\/report-store\/pd-L1-inhibitors-market\">PD-1 or PD-L1 inhibitor therapy<\/a>. In plain terms, patients whose tumors don&#8217;t express enough PD-L1 to qualify for checkpoint inhibitors, roughly 70% of all TNBC patients, now have an ADC option from day one, instead of starting with chemotherapy alone.<\/p>\n\n\n\n<p>The approval is built on the <strong>Phase 3 ASCENT-03 trial<\/strong>, which compared TRODELVY monotherapy against standard-of-care chemotherapy in this PD-(L)1-ineligible population. The results were compelling: TRODELVY cut the risk of disease progression or death by 38%, with median progression-free survival climbing to 9.7 months versus 6.9 months for chemotherapy. The European Commission&#8217;s decision made TRODELVY the first ADC approved in front-line metastatic TNBC across the EU&#8217;s 27 member states plus Norway, Iceland, and Liechtenstein, and Gilead is calling it the first genuinely new treatment option for this patient group in roughly 20 years. The FDA followed less than 24 hours later with a matching nod, then layered on a second TNBC expansion in the same announcement.<\/p>\n\n\n\n<p>Gilead also has a combination filing in play: TRODELVY plus <strong>Merck&#8217;s KEYTRUDA<\/strong> for PD-L1-positive front-line metastatic TNBC, based on the <strong>Phase 3 ASCENT-04 study<\/strong>, which is under review with both the FDA and EMA. If that combination clears, Gilead&#8217;s ambition becomes clear: TRODELVY as a backbone therapy across the entire <a href=\"https:\/\/www.delveinsight.com\/report-store\/triple-negative-breast-cancer-tnbc-market\">front-line TNBC population<\/a>, regardless of PD-L1 status.<\/p>\n\n\n\n<p>For patients and caregivers searching for information on TRODELVY life expectancy, the honest answer is nuanced and depends heavily on the treatment setting. In the original second-line or later metastatic TNBC indication, TRODELVY remains the only Trop-2-directed ADC to show a meaningful overall survival benefit, and Gilead notes it&#8217;s been used in more than <strong>75,000<\/strong> breast cancer patients across over <strong>60 countries<\/strong> over six years.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-the-trodelvy-track-record-not-a-clean-sweep\"><span class=\"ez-toc-section\" id=\"The_TRODELVY_Track_Record_Not_a_Clean_Sweep\"><\/span><strong>The TRODELVY Track Record: Not a Clean Sweep<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<p>It&#8217;s worth being honest about the bigger picture, because this approval doesn&#8217;t arrive in a vacuum. TRODELVY first won accelerated FDA approval in 2020 for previously treated metastatic TNBC, then converted to full approval a year later after a confirmatory trial showed it improved both progression-free and overall survival, a first for that indication. Gilead leaned hard on TRODELVY&#8217;s potential, partly to justify its roughly <strong>$21 billion<\/strong> acquisition of <strong>Immunomedics<\/strong>, the company that originally developed the drug.<\/p>\n\n\n\n<p>But the road has been bumpy since. Gilead voluntarily withdrew TRODELVY&#8217;s accelerated approval in bladder cancer after a confirmatory trial failed. The drug also missed its primary survival endpoint in a high-profile <strong>Phase 3 study (EVOKE-01)<\/strong> in previously treated TRODELVY NSCLC patients, and a follow-on combination trial pairing TRODELVY with KEYTRUDA in front-line lung cancer was halted after an independent monitoring committee found the data unlikely to reach statistical significance. Most recently, TRODELVY also stumbled in a <a href=\"https:\/\/www.delveinsight.com\/report-store\/hr-positive-her2-negative-breast-cancer-market-insights\">first-line HR+\/HER2-negative metastatic breast cancer trial<\/a>, missing its progression-free survival endpoint, though an early, and still immature, trend favored TRODELVY on overall survival.<\/p>\n\n\n\n<figure class=\"wp-block-image size-large\"><img decoding=\"async\" width=\"1024\" height=\"337\" src=\"https:\/\/www.delveinsight.com\/blog\/wp-content\/uploads\/2026\/06\/TRODELVY-Approval-Timeline-1024x337.webp\" alt=\"TRODELVY-Approval-Timeline\" class=\"wp-image-35577\" srcset=\"https:\/\/www.delveinsight.com\/blog\/wp-content\/uploads\/2026\/06\/TRODELVY-Approval-Timeline-1024x337.webp 1024w, https:\/\/www.delveinsight.com\/blog\/wp-content\/uploads\/2026\/06\/TRODELVY-Approval-Timeline-300x99.webp 300w, https:\/\/www.delveinsight.com\/blog\/wp-content\/uploads\/2026\/06\/TRODELVY-Approval-Timeline-150x49.webp 150w, https:\/\/www.delveinsight.com\/blog\/wp-content\/uploads\/2026\/06\/TRODELVY-Approval-Timeline-768x252.webp 768w, https:\/\/www.delveinsight.com\/blog\/wp-content\/uploads\/2026\/06\/TRODELVY-Approval-Timeline-1536x505.webp 1536w, https:\/\/www.delveinsight.com\/blog\/wp-content\/uploads\/2026\/06\/TRODELVY-Approval-Timeline.webp 1920w\" sizes=\"(max-width: 1024px) 100vw, 1024px\" \/><\/figure>\n\n\n\n<p>The front-line TNBC win matters precisely because of this context. It&#8217;s Gilead&#8217;s clearest evidence yet that TRODELVY&#8217;s core franchise, TNBC, remains durable, even as the drug has struggled to expand cleanly into adjacent tumor types.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-trodelvy-vs-datroway-the-defining-rivalry-in-trop2-adcs\"><span class=\"ez-toc-section\" id=\"TRODELVY_vs_DATROWAY_The_Defining_Rivalry_in_TROP2_ADCs\"><\/span><strong>TRODELVY vs. DATROWAY: The Defining Rivalry in TROP2 ADCs<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<p>No conversation about this approval is complete without addressing TRODELVY vs DATROWAY, because AstraZeneca and Daiichi Sankyo actually beat Gilead to the front-line TNBC finish line in the US. DATROWAY (datopotamab deruxtecan) received FDA approval for the same PD-(L)1-ineligible front-line TNBC population about a month before TRODELVY&#8217;s expanded nod arrived.<\/p>\n\n\n\n<p>The two companies are now waging a head-to-head data war. DATROWAY&#8217;s <strong>Phase 3 TROPION-Breast02 trial<\/strong> showed a 21% reduction in the risk of death versus chemotherapy, extending median overall survival to 23.7 months, and AstraZeneca\/Daiichi have been quick to point out that DATROWAY is currently the only Trop-2-directed ADC to demonstrate an overall survival benefit in this specific front-line setting. By contrast, Gilead&#8217;s ASCENT-03 data, presented at the <a href=\"https:\/\/www.delveinsight.com\/events\/esmo-conference-2025\"><strong>2025 European Society for Medical Oncology Congress<\/strong><\/a>, didn&#8217;t reach statistical significance on overall survival in the comparable population, even though it cleared the bar on progression-free survival.<\/p>\n\n\n\n<p>Industry oncologists don&#8217;t see this as a knockout, though. A recent physician survey found views split: some experts believe DATROWAY&#8217;s overall survival data will tilt early prescribing in its favor, while others argue there&#8217;s no clear winner and expect the two drugs to split the market fairly evenly, at least initially. Both TRODELVY and DATROWAY have already secured Category 1, the highest tier of recommendation, in NCCN guidelines for front-line TNBC, and Gilead&#8217;s commercial leadership has reported early TRODELVY uptake in this setting, even ahead of the formal FDA nod.<\/p>\n\n\n\n<p>There&#8217;s also a third entrant to watch: <strong>Kelun-Biotech&#8217;s Merck-partnered sacituzumab tirumotecan (sac-TMT)<\/strong>, which has already cleared regulatory hurdles in China for previously treated TNBC and recently posted a positive Phase 3 readout in front-line TNBC there as well. The Trop2 ADCs category isn&#8217;t a two-horse race anymore; it&#8217;s a genuine three-way global contest, and pricing, sequencing, and biomarker testing patterns will likely decide who wins which markets.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-why-tnbc-is-such-high-stakes-real-estate\"><span class=\"ez-toc-section\" id=\"Why_TNBC_is_Such_High-Stakes_Real_Estate\"><\/span><strong>Why TNBC is Such High-Stakes Real Estate?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<p>Triple-negative breast cancer earns its reputation as the toughest breast cancer subtype to treat. It accounts for roughly <strong>10-15%<\/strong> of all breast cancers, but disproportionately affects younger, premenopausal women, and Black and Hispanic patients. Because TNBC tumors lack estrogen receptors, progesterone receptors, and meaningful HER2 expression, the entire toolbox of hormone therapies and HER2-targeted drugs that work for other breast cancer subtypes simply doesn&#8217;t apply. That&#8217;s left oncologists with a much thinner arsenal, and it&#8217;s exactly why an effective ADC, with or without a perfect overall survival readout, represents real clinical news rather than incremental noise.<\/p>\n\n\n\n<p>About <strong>40%<\/strong> of TNBC tumors express PD-L1, qualifying those patients for checkpoint inhibitor-based regimens. That leaves the remaining <strong>60-70%<\/strong>,&nbsp; the exact population TRODELVY&#8217;s new approval targets, without an immunotherapy pathway, historically defaulting straight to chemotherapy. This is the gap both TRODELVY and DATROWAY are now racing to fill, and it&#8217;s a big reason analysts have called recent first-line TNBC data &#8220;practice-changing&#8221;: doctors already trust TRODELVY as the most-prescribed branded therapy in second-line TNBC, and that comfort level is expected to translate into front-line uptake even before head-to-head data fully shakes out.<\/p>\n\n\n\n<p>The broader triple-negative breast cancer TNBC treatment market has shifted dramatically in just the past 18 months. A few years ago, front-line metastatic TNBC essentially meant chemotherapy, with checkpoint inhibitors layered in only for the PD-L1-positive minority. Now, in the span of about a month, two different Trop2-directed ADCs have secured front-line approval in the US for the PD-(L)1-ineligible population, with a third candidate advancing in China. That&#8217;s an extraordinarily fast pace of change for a disease segment that had gone two decades without a genuinely new option in Europe.<\/p>\n\n\n\n<p>This also reshapes the adjuvant <a href=\"https:\/\/www.delveinsight.com\/report-store\/triple-negative-breast-cancer-tnbc-pipeline-insight\">TNBC competitors<\/a> Gilead marketed products landscape and the broader question of who else is contesting Gilead&#8217;s territory. Beyond DATROWAY and sac-TMT in the metastatic setting, the competitors of Gilead adjuvant TNBC marketed products picture includes established checkpoint inhibitor-chemotherapy combinations and PARP inhibitors used in BRCA-mutated early-stage disease, all of which continue to compete for position across the TNBC treatment continuum, from neoadjuvant and adjuvant settings through to later-line metastatic care. Gilead&#8217;s strategy is clearly to anchor TRODELVY as the backbone option across as many of these settings as the data will support, while AstraZeneca and Daiichi pursue an aggressive survival-data-first positioning with DATROWAY.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-conclusion\"><span class=\"ez-toc-section\" id=\"Conclusion\"><\/span><strong>Conclusion<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<p>Gilead&#8217;s front-line TNBC approval is a genuine win, and a needed one, but it lands in a market that no longer hands out easy victories. TRODELVY enters this new chapter with real strengths: a long track record, deep physician trust, and now a statistically robust progression-free survival benefit in a previously underserved patient population. What it doesn&#8217;t yet have, at least in this specific setting, is the overall survival data that its closest rival can already claim. Whether that gap matters to prescribers as much as familiarity and sequencing convenience do will likely determine how this three-way TROP2 ADC contest plays out over the next two years, and it&#8217;s a story every TNBC stakeholder, from oncologists to payers to competitors, will be watching closely.<\/p>\n\n\n\n<figure class=\"wp-block-image size-large\"><a href=\"https:\/\/www.delveinsight.com\/report-store\/metastatic-triple-negative-breast-cancer-market\"><img decoding=\"async\" width=\"1024\" height=\"194\" src=\"https:\/\/www.delveinsight.com\/blog\/wp-content\/uploads\/2026\/06\/Metastatic-Triple-Negative-Breast-Cancer-Market-Outlook-1024x194.webp\" alt=\"Metastatic Triple-Negative Breast Cancer Market Outlook\" class=\"wp-image-35576\" srcset=\"https:\/\/www.delveinsight.com\/blog\/wp-content\/uploads\/2026\/06\/Metastatic-Triple-Negative-Breast-Cancer-Market-Outlook-1024x194.webp 1024w, https:\/\/www.delveinsight.com\/blog\/wp-content\/uploads\/2026\/06\/Metastatic-Triple-Negative-Breast-Cancer-Market-Outlook-300x57.webp 300w, https:\/\/www.delveinsight.com\/blog\/wp-content\/uploads\/2026\/06\/Metastatic-Triple-Negative-Breast-Cancer-Market-Outlook-150x28.webp 150w, https:\/\/www.delveinsight.com\/blog\/wp-content\/uploads\/2026\/06\/Metastatic-Triple-Negative-Breast-Cancer-Market-Outlook-768x145.webp 768w, https:\/\/www.delveinsight.com\/blog\/wp-content\/uploads\/2026\/06\/Metastatic-Triple-Negative-Breast-Cancer-Market-Outlook-1536x291.webp 1536w, https:\/\/www.delveinsight.com\/blog\/wp-content\/uploads\/2026\/06\/Metastatic-Triple-Negative-Breast-Cancer-Market-Outlook.webp 1584w\" sizes=\"(max-width: 1024px) 100vw, 1024px\" \/><\/a><\/figure>\n","protected":false},"excerpt":{"rendered":"<p>Summary For nearly two decades, patients with metastatic triple-negative breast cancer (TNBC) who couldn&#8217;t tolerate immunotherapy had no new options. That changed this week. Gilead Sciences just landed back-to-back regulatory wins for TRODELVY (sacituzumab govitecan-hziy), first from the European Commission, then a day later from the US FDA, clearing the Trop-2-directed antibody-drug conjugate (ADC) as [&hellip;]<\/p>\n","protected":false},"author":14,"featured_media":35574,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"_editorskit_title_hidden":false,"_editorskit_reading_time":0,"_editorskit_is_block_options_detached":false,"_editorskit_block_options_position":"{}","advgb_blocks_editor_width":"","advgb_blocks_columns_visual_guide":"","footnotes":""},"categories":[17],"tags":[21889,23028,22125,2014,19237,20399,23029],"industry":[17225],"therapeutic_areas":[17228],"class_list":["post-35572","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-articles","tag-metastatic-triple-negative-breast-cancer-2","tag-mtnbc","tag-pd-l1-inhibitors","tag-tnbc","tag-triple-negative-breast-cancer-2","tag-trodelvy","tag-trop2-adc","industry-pharmaceutical","therapeutic_areas-oncology"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v25.8 (Yoast SEO v25.8) - https:\/\/yoast.com\/wordpress\/plugins\/seo\/ -->\n<title>TRODELVY\u2019s 1L mTNBC Approval Changes the ADC Battlefield<\/title>\n<meta name=\"description\" content=\"Gilead&#039;s TRODELVY redefines first-line mTNBC treatment as the only approved ADC independent of PD-L1 expression.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.delveinsight.com\/blog\/trodelvy-approval-for-mtnbc\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"TRODELVY\u2019s 1L mTNBC Approval Changes the ADC Battlefield\" \/>\n<meta property=\"og:description\" content=\"Gilead&#039;s TRODELVY redefines first-line mTNBC treatment as the only approved ADC independent of PD-L1 expression.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.delveinsight.com\/blog\/trodelvy-approval-for-mtnbc\" \/>\n<meta property=\"og:site_name\" content=\"DelveInsight Business Research\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/DelveInsight-1423323754607782\/\" \/>\n<meta property=\"article:published_time\" content=\"2026-06-26T09:56:47+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2026-06-26T09:56:49+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.delveinsight.com\/blog\/wp-content\/uploads\/2026\/06\/trodelvy-approval-for-mtnbc.webp\" \/>\n\t<meta property=\"og:image:width\" content=\"466\" \/>\n\t<meta property=\"og:image:height\" content=\"284\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/webp\" \/>\n<meta name=\"author\" content=\"Sandeep Joshi\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:creator\" content=\"@DelveInsight\" \/>\n<meta name=\"twitter:site\" content=\"@DelveInsight\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Sandeep Joshi\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"8 minutes\" \/>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"TRODELVY\u2019s 1L mTNBC Approval Changes the ADC Battlefield","description":"Gilead's TRODELVY redefines first-line mTNBC treatment as the only approved ADC independent of PD-L1 expression.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.delveinsight.com\/blog\/trodelvy-approval-for-mtnbc","og_locale":"en_US","og_type":"article","og_title":"TRODELVY\u2019s 1L mTNBC Approval Changes the ADC Battlefield","og_description":"Gilead's TRODELVY redefines first-line mTNBC treatment as the only approved ADC independent of PD-L1 expression.","og_url":"https:\/\/www.delveinsight.com\/blog\/trodelvy-approval-for-mtnbc","og_site_name":"DelveInsight Business Research","article_publisher":"https:\/\/www.facebook.com\/DelveInsight-1423323754607782\/","article_published_time":"2026-06-26T09:56:47+00:00","article_modified_time":"2026-06-26T09:56:49+00:00","og_image":[{"width":466,"height":284,"url":"https:\/\/www.delveinsight.com\/blog\/wp-content\/uploads\/2026\/06\/trodelvy-approval-for-mtnbc.webp","type":"image\/webp"}],"author":"Sandeep Joshi","twitter_card":"summary_large_image","twitter_creator":"@DelveInsight","twitter_site":"@DelveInsight","twitter_misc":{"Written by":"Sandeep Joshi","Est. reading time":"8 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/www.delveinsight.com\/blog\/trodelvy-approval-for-mtnbc","url":"https:\/\/www.delveinsight.com\/blog\/trodelvy-approval-for-mtnbc","name":"TRODELVY\u2019s 1L mTNBC Approval Changes the ADC Battlefield","isPartOf":{"@id":"https:\/\/www.delveinsight.com\/blog\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.delveinsight.com\/blog\/trodelvy-approval-for-mtnbc#primaryimage"},"image":{"@id":"https:\/\/www.delveinsight.com\/blog\/trodelvy-approval-for-mtnbc#primaryimage"},"thumbnailUrl":"https:\/\/www.delveinsight.com\/blog\/wp-content\/uploads\/2026\/06\/trodelvy-approval-for-mtnbc.webp","datePublished":"2026-06-26T09:56:47+00:00","dateModified":"2026-06-26T09:56:49+00:00","author":{"@id":"https:\/\/www.delveinsight.com\/blog\/#\/schema\/person\/f1eefd8dd4afdb0617d6166f8b301e0a"},"description":"Gilead's TRODELVY redefines first-line mTNBC treatment as the only approved ADC independent of PD-L1 expression.","inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.delveinsight.com\/blog\/trodelvy-approval-for-mtnbc"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.delveinsight.com\/blog\/trodelvy-approval-for-mtnbc#primaryimage","url":"https:\/\/www.delveinsight.com\/blog\/wp-content\/uploads\/2026\/06\/trodelvy-approval-for-mtnbc.webp","contentUrl":"https:\/\/www.delveinsight.com\/blog\/wp-content\/uploads\/2026\/06\/trodelvy-approval-for-mtnbc.webp","width":466,"height":284,"caption":"trodelvy-approval-for-mtnbc"},{"@type":"WebSite","@id":"https:\/\/www.delveinsight.com\/blog\/#website","url":"https:\/\/www.delveinsight.com\/blog\/","name":"DelveInsight Business Research","description":"Blog","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.delveinsight.com\/blog\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.delveinsight.com\/blog\/#\/schema\/person\/f1eefd8dd4afdb0617d6166f8b301e0a","name":"Sandeep Joshi","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.delveinsight.com\/blog\/#\/schema\/person\/image\/","url":"https:\/\/secure.gravatar.com\/avatar\/7676451175fe155887a18ffb50e674b270d87436a3fc34ca206f86921cddf4cd?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/7676451175fe155887a18ffb50e674b270d87436a3fc34ca206f86921cddf4cd?s=96&d=mm&r=g","caption":"Sandeep Joshi"},"sameAs":["http:\/\/Delveinsight.com"]}]}},"author_meta":{"display_name":"Sandeep Joshi","author_link":"https:\/\/www.delveinsight.com\/blog\/author\/sjoshidelveinsight-com"},"featured_img":"https:\/\/www.delveinsight.com\/blog\/wp-content\/uploads\/2026\/06\/trodelvy-approval-for-mtnbc-300x183.webp","coauthors":[],"tax_additional":{"categories":{"linked":["<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">Articles<\/a>"],"unlinked":["<span class=\"advgb-post-tax-term\">Articles<\/span>"]},"tags":{"linked":["<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">metastatic triple-negative breast cancer<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">mTNBC<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">PD-(L)1 Inhibitors<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">TNBC<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">Triple-Negative Breast Cancer<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">Trodelvy<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">TROP2 ADC<\/a>"],"unlinked":["<span class=\"advgb-post-tax-term\">metastatic triple-negative breast cancer<\/span>","<span class=\"advgb-post-tax-term\">mTNBC<\/span>","<span class=\"advgb-post-tax-term\">PD-(L)1 Inhibitors<\/span>","<span class=\"advgb-post-tax-term\">TNBC<\/span>","<span class=\"advgb-post-tax-term\">Triple-Negative Breast Cancer<\/span>","<span class=\"advgb-post-tax-term\">Trodelvy<\/span>","<span class=\"advgb-post-tax-term\">TROP2 ADC<\/span>"]}},"comment_count":"0","relative_dates":{"created":"Posted 6 hours ago","modified":"Updated 6 hours ago"},"absolute_dates":{"created":"Posted on Jun 26, 2026","modified":"Updated on Jun 26, 2026"},"absolute_dates_time":{"created":"Posted on Jun 26, 2026 3:26 pm","modified":"Updated on Jun 26, 2026 3:26 pm"},"featured_img_caption":"trodelvy-approval-for-mtnbc","series_order":"","_links":{"self":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts\/35572","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/users\/14"}],"replies":[{"embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/comments?post=35572"}],"version-history":[{"count":2,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts\/35572\/revisions"}],"predecessor-version":[{"id":35578,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts\/35572\/revisions\/35578"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/media\/35574"}],"wp:attachment":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/media?parent=35572"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/categories?post=35572"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/tags?post=35572"},{"taxonomy":"industry","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/industry?post=35572"},{"taxonomy":"therapeutic_areas","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/therapeutic_areas?post=35572"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}